Year-end Sale % OFF 
Abstract
The introduction of new therapeutics for patients with chronic heart failure, including sacubitril/valsartan, sodium-glucose cotransporter 2 inhibitors, and ivabradine, in addition to beta-blockers, angiotensin converting enzyme inhibitors, and mineralocorticoid receptor antagonists, lends an opportunity for significant clinical risk reduction compared to what was available just one decade ago. Further clinical options are needed, however, for patients with residual clinical congestion refractory to these therapies. Adaptive servo-ventilation is a novel therapeutic option to address significant clinical volume in cases resistant to medical therapy. The aggregate benefit of these additional therapeutic strategies in addition to foundational medical therapy may be a promising option in the selected candidates who do not achieve acceptable clinical and quality-of-life improvements with oral medical therapy alone. Now is the era to reconsider the implication of an adaptive servo-ventilation-therapy-incorporated medical therapeutic strategy for patients with congestive heart failure.
Highlights
IntroductionIn addition to the survival benefit, improvement in patient-reported outcomes including functional status and quality of life is of paramount importance [4]
Med. 2022, 11, Several novel therapies have been introduced over the last decade that both improve quality of life and reduce mortality in patients with chronic heart failure, including sacubitril/valsartan (ARNI), sodium-glucose cotransporter 2 (SGLT2) inhibitor, and ivabradine [1]
Themortality secondary analysis demonstrated efficacy chronic heart failure to reduce and morbidity comparedreduced to the enalapril of sacubitril/valsartan in patients with multiple signs of congestion based on clinical arm in the PARADIGM-HF trial [15]
Summary
In addition to the survival benefit, improvement in patient-reported outcomes including functional status and quality of life is of paramount importance [4]. Much of this is related to the treatment of congestion. Tolvaptan as a diuretic therapy improves pulmonary/systemic congestion while not worsening renal function [8] The cost of this medication in addition to lack of evidence when combined with contemporary heart. The cost of this medication in addition to lack of evidence when combined with contemporary heart failure therapies are limiting factors to justify the widespread implementafailure areThere limiting factors justify thefor widespread implementation of tolvaptan. In discussed the era when novel medical agents have been introduced, if appropriately utilized as discussed in this review
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
